Despite the extensive research that has been conducted on the use of small molecule inhibitors for EGFR and relevant downstream signalling pathways, little evidence supports improved GBM patient outcomes, compared with standard TMZ treatment [20,23,24]. This evidence concerns the gene EGFR and glioblastoma.